乳腺癌患者血清PPAR-γ基因甲基化qPCR检测及临床意义  

Detection and clinical significance of serum PPAR-γ gene methylation in patient with breast cancer

作　　者：韦美德[1] 董家书[1] 周格琛[1] 邓开凤[1] 戴盛明[1] WEI Meide;DONG Jiashu;ZHOU Gechen;DENG Kaifeng;DAI Shengming(Department of Laboratory Medicine,the Fourth Affiliated Hospital of Guangxi Medical University Liuzhou,Guangxi,China,54500)

机构地区：[1]广西医科大学附属第四医院检验科,广西柳州545005

出　　处：《分子诊断与治疗杂志》2018年第4期241-245,267,共6页Journal of Molecular Diagnostics and Therapy

基　　金：BEAMing技术定量检测乳腺癌患者外周血PPAR-γ甲基化及临床应用(2015J030510)

摘　　要：目的建立血清过氧化物酶体增殖物激活受体-γ(peroxisome proliferator-activated receptor-γ,PPAR-γ)基因甲基化状态的荧光定量检测方法,并分析PPAR-γ基因甲基化与临床病理参数的相关性,探讨其在乳腺癌疾病筛查与诊断方面的应用价值。方法收集乳腺癌患者153例,乳腺囊肿66例与乳腺增生124例,健康对照50例,实时荧光定量PCR(real-time fluorescent quantive PCR,qPCR)检测PPAR-γ基因甲基化状态,结合患者临床资料分析该基因甲基化状态与乳腺癌病理特点的相关性。结果乳腺癌、乳腺囊肿、乳腺增生和健康对照血清中PPAR-γ基因甲基化检出率分别为54.9%、45.5%、41.1%和16%,疾病组均显著高于对照组,差异有统计学意义(P<0.05)。乳腺癌患者PPAR-γ基因甲基化检出率显著高于乳腺增生(P<0.05),乳腺囊肿与乳腺增生甲基化检出率无显著差异(P>0.05)。乳腺癌患者基因甲基化检出率与患者年龄、肿瘤分期、病理类型、淋巴结转移差异均无统计学意义(P>0.05)。PPAR-γ基因甲基化水平为:乳腺癌32.3%~50.2%,乳腺囊肿27.7%~44.9%,乳腺增生25.6%~42.5%,健康对照20.2%~30.6%。疾病组PPAR-γ基因甲基化水平均显著高于正常对照组(P<0.05)。结论乳腺癌患者血清PPAR-γ基因发生甲基化程度增高,有可能成为辅助筛查乳腺癌的手段。Objective To establish a real-time fluorescence quantitative methylation assay for investigating the methylation status of peroxisome proliferator-activated receptor-γ（PPAR-γ）gene in breast cancer,and analyze the correlation between PPAR-γ gene methylation with clinicopathologic parameters,and the clinical significance in screening and diagnosis for breast cancer. Methods 393 serum samples were collected from 153 patients with breast cancer,66 patients with breast cyst,124 patients with breast hyperplasia and 50 individuals from healthy physical examination as controls. The methylation status of PPARg gene in these serum samples were detected by real-time fluorescent quantitative PCR（q PCR）. Combined with the clinical data of patients,the correlation between the methylation status of PPAR-γ gene and the pathologic features of breast cancer was analyzed to evaluate its screening and diagnostic value for breast cancer. Results The detection rates of PPAR-γ methylation were 54.9%（breast cancer）,45.5%（breast cyst）,41.1%（breast hyperplasia）and 16%（health control group）. The frequency of methylation of PPAR-γ gene in patients with breast cancer was significantly higher than that in patients with breast hyperplasia（P〈0.05）. There was no significant difference between breast cysts and breast hyperplasia（P〈0.05）. The frequency of methylation of PPAR-γ gene in diseases groups was significantly higher than that in the healthy control group. The aberrant methylation of PPAR-γ gene in breast cancer serums had no correlation with patient.s age,tumor stage,pathological type and lymphatic metastasis（P〈0.05）. The methylation levels of PPAR-γ gene were 32.3%-50.2% in breast cancer,27.7%-44.9% in breast cyst,25.6%-42.5% in breast hyperplasia,and 20.2%-30.6% in health control group. The methylation levels of PPAR-γ gene were significantly higher thanthat in the healthy control group. Conclusion In this study,q PCR assay was established to investigate the methylation status of PPAR-

关 键 词：乳腺癌 PPAR-Γ 甲基化 

分 类 号：R730.43[医药卫生—肿瘤] R737.9[医药卫生—临床医学]